during the swiftly evolving field of oncology exploration, correct and productive mutation screening is very important for establishing targeted therapies. The KRAS companies Platform performs a pivotal part During this landscape by presenting extensive answers for KRAS mutation profiling and analysis. KRAS mutations, present in approximately 95% o